ArticlePharmaceutical research2007
Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B.
Article in Pharmaceutical research, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Pulmonary Targeting of Levofloxacin Using Microsphere-Based Dry Powder Inhalation.Pharmaceuticals (Basel, Switzerland) · 2022Article
- CFP10-loaded PLGA nanoparticles as a booster vaccine confer protective immunity againstBioImpacts : BI · 2022Article
- Harnessing Dendritic Cells for Poly (D,L-lactide-Frontiers in immunology · 2019Review
- Recent advances in the treatment of pathogenic infections using antibiotics and nano-drug delivery vehicles.Drug design, development and therapy · 2019Review
- Potential of polymeric particles as future vaccine delivery systems/adjuvants for parenteral and non-parenteral immunization against tuberculosis: A systematic review.Iranian journal of basic medical sciences · 2018Review
- Article
- Developments in the formulation and delivery of spray dried vaccines.Human vaccines & immunotherapeutics · 2017Review
- Article
- Scale of health: indices of safety and efficacy in the evolving environment of large biological datasets.Pharmaceutical research · 2014Review
- Mouse model for efficacy testing of antituberculosis agents via intrapulmonary delivery.Antimicrobial agents and chemotherapy · 2012Article
- Microneedle-mediated vaccine delivery: harnessing cutaneous immunobiology to improve efficacy.Expert opinion on drug delivery · 2012Review
- Pharmaceutical aerosols for the treatment and prevention of tuberculosis.Frontiers in cellular and infection microbiology · 2012Review
- Article
- Pulmonary immunization using antigen 85-B polymeric microparticles to boost tuberculosis immunity.The AAPS journal · 2010Article
- Rational design of multiple TB antigens TB10.4 and TB10.4-Ag85B as subunit vaccine candidates against Mycobacterium tuberculosis.Pharmaceutical research · 2010Article
- PLGA microparticles in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen TB10.4-Ag85B.Pharmaceutical research · 2010Article
- Screening for potential adjuvants administered by the pulmonary route for tuberculosis vaccines.The AAPS journal · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
purposeTo investigate the use of poly (lactide-co-glycolide) (PLGA) microparticles in respirable sizes as carriers for Antigen 85B (Ag85B), a secreted protein of Mycobacterium tuberculosis, with the ultimate goal of employing them in pulmonary delivery of tuberculosis vaccine. MATERIALS AND
methodsRecombinant Ag85B was expressed from two Escherichia coli strains and encapsulated by spray-drying in PLGA microspheres with/without adjuvants. These microspheres containing rAg85B were assessed for their ability to deliver antigen to macrophages for subsequent processing and presentation to the specific CD4 T-hybridoma cells DB-1. DB-1 cells recognize the Ag85B(97-112) epitope presented in the context of MHC class II and secrete IL-2 as the cytokine marker.
resultsMicrospheres suitable for aerosol delivery to the lungs (3.4-4.3 microm median diameter) and targeting alveolar macrophages were manufactured. THP-1 macrophage-like cells exposed with PLGA-rAg85B microspheres induced the DB-1 cells to produce IL-2 at a level that was two orders of magnitude larger than the response elicited by soluble rAg85B. This formulation demonstrated extended epitope presentation.
conclusionsPLGA microspheres in respirable sizes were effective in delivering rAg85B in an immunologically relevant manner to macrophages. These results are a foundation for further investigation into the potential use of PLGA particles for delivery of vaccines to prevent M. tuberculosis infection.
Indexed as
Identifiers
17657598What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.